By Jeremy I Levin; Stefan Laufer
Content material: part 1. Arachidonic acid cascade -- part 2. Kinases -- part three. GPCRs -- part four. Sphingolipids -- part five. Steroid hormone receptors
Read or Download Anti-Inflammatory Drug Discovery PDF
Similar pharmacy books
Whereas the genomic revolution has quick resulted in the deposit of greater than 30,000 constructions within the protein facts financial institution (PDB), below one percentage of these contributions characterize membrane proteins although membrane proteins represent a few 20 percentage of all proteins. This discrepancy turns into considerably problematic while it's coupled with the truth that 60 percentage of present medicines are according to focusing on this staff of proteins, a development that doesn't look more likely to opposite.
With contribution through various specialists
Biotechnology and Biopharmaceuticals: remodeling Proteins and Genes into medications, moment version addresses the pivotal matters on the subject of translational technological know-how, together with preclinical and medical drug improvement, regulatory technological know-how, pharmaco-economics and cost-effectiveness concerns. the recent version additionally offers an replace on new proteins and genetic medicinal drugs, the translational and built-in sciences that proceed to gasoline the suggestions in medication, in addition to the recent parts of healing improvement together with melanoma vaccines, stem mobilephone therapeutics, and cell-based cures.
The 1st expert reference in this hugely suitable subject, for drug builders, pharmacologists and toxicologists. The authors supply greater than a scientific evaluate of computational instruments and information bases for drug metabolism learn and their underlying ideas. they target to exhibit their specialist wisdom distilled from a long time of expertise within the box.
- FDA Bioequivalence Standards
- Encyclopedia of Pharmacology Research
- Active Pharmaceutical Ingredients. Development, Manufacturing, and Regulation
- Pharmaceutical Process Scale-Up
- Pharmaceutical dosage forms--tablets
- Textbook of Receptor Pharmacology, Third Edition
Extra info for Anti-Inflammatory Drug Discovery
Avis, S. H. Hong, A. Martinez, T. Moody, Y. H. Choi, J. Trepel, R. Das, M. Jett and J. L. , 2001, 15, 2007. 32 Chapter 1 169. M. Romano, A. Catalano, M. Nutini, E. D’Urbano, C. Crescenzi, J. Claria, R. Libner, G. Davi and A. , 2001, 15, 2326. 170. J. Ghosh and C. E. Myers, Proc. Natl Acad. Sci. USA, 1998, 95, 13182. 171. M. Mehrabian and H. Allayee, Curr. Opin. , 2003, 14, 447. 172. C. D. Funk, Nat. Rev. , 2005, 4, 664. 173. F. Celotti and S. Laufer, Pharmacol. , 2001, 43, 429. 174. B. K. Lam, J.
S. Gilmour and M. D. Mitchell, Mol. , 2005, 68, 169. 1–7 When the liberated fatty acid is arachidonic acid, subsequent metabolism through the cyclooxygenase (COX) and the lipoxygenase (LOX) pathways leads to the formation of eicosanoids, including prostaglandins and leukotrienes. A subset of lysophospholipids (1-O-alkyl-substituted choline glycerophospholipids) can be acetylated to the platelet-activating factor (PAF). 12–20 The special attraction of this approach is based on the evidence that, unlike cyclooxygenase inhibitors, inhibitors of PLA2 not only reduce the formation of prostaglandins, but also suppress the generation of leukotrienes, lysophospholipids and the PAF.
Myers, Proc. Natl Acad. Sci. USA, 1998, 95, 13182. 171. M. Mehrabian and H. Allayee, Curr. Opin. , 2003, 14, 447. 172. C. D. Funk, Nat. Rev. , 2005, 4, 664. 173. F. Celotti and S. Laufer, Pharmacol. , 2001, 43, 429. 174. B. K. Lam, J. F. Penrose, J. Rokach, K. Xu, M. H. Baldasaro and K. F. Austen, Eur. J. , 1996, 238, 606. 175. A. Koeberle, U. Siemoneit, H. Northoﬀ, B. Hofmann, G. Schneider and O. Werz, Eur. J. , 2009, 608, 84. 176. A. Koeberle, U. Siemoneit, U. Buehring, H. Northoﬀ, S. Laufer, W.